S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
NASDAQ:GMTX

Gemini Therapeutics (GMTX) Stock Forecast, Price & News

$48.91
-0.09 (-0.18%)
(As of 09/22/2023 ET)
Compare
Today's Range
$47.84
$49.24
50-Day Range
$45.61
$55.93
52-Week Range
$1.16
$14.10
Volume
87,330 shs
Average Volume
189,291 shs
Market Capitalization
$2.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GMTX stock logo

About Gemini Therapeutics (NASDAQ:GMTX) Stock

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

GMTX Price History

GMTX Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Gemini Horoscope
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMTX, RMED, LOTZ
See More Headlines
Receive GMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GMTX Company Calendar

Last Earnings
11/15/2021
Today
9/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GMTX
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Net Income
$-71,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.89 per share

Miscellaneous

Free Float
37,739,000
Market Cap
$2.12 billion
Optionable
Optionable
Beta
-0.12
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Georges Gemayel C.F.A. (Age 62)
    Ph.D., Interim Pres & CEO and Exec. Chairperson
    Comp: $256.73k
  • Mr. Brian Piekos (Age 46)
    Chief Bus. Officer, CFO, Principal Accounting & Principal Financial Officer
    Comp: $549.73k
  • Mr. Jason Patrick Meyenburg M.B.A.Mr. Jason Patrick Meyenburg M.B.A. (Age 44)
    M.D., Advisor
    Comp: $715.96k
  • Mr. Patrick Truesdell (Age 41)
    VP of Fin. & Controller













GMTX Stock - Frequently Asked Questions

How have GMTX shares performed in 2023?

Gemini Therapeutics' stock was trading at $19.89 at the beginning of the year. Since then, GMTX shares have increased by 145.9% and is now trading at $48.91.
View the best growth stocks for 2023 here
.

How were Gemini Therapeutics' earnings last quarter?

Gemini Therapeutics, Inc. (NASDAQ:GMTX) released its earnings results on Monday, November, 15th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.04.

What is Gemini Therapeutics' stock symbol?

Gemini Therapeutics trades on the NASDAQ under the ticker symbol "GMTX."

How do I buy shares of Gemini Therapeutics?

Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gemini Therapeutics' stock price today?

One share of GMTX stock can currently be purchased for approximately $48.91.

How much money does Gemini Therapeutics make?

Gemini Therapeutics (NASDAQ:GMTX) has a market capitalization of $2.12 billion. The company earns $-71,870,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How can I contact Gemini Therapeutics?

Gemini Therapeutics' mailing address is C/O FORESITE CAPITAL 600 MONTGOMERY ST SUITE 4500, SAN FRANCISCO CA, 94111. The official website for the company is www.geminitherapeutics.com. The company can be reached via phone at 415-877-4887 or via email at gemini@argotpartners.com.

This page (NASDAQ:GMTX) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -